Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.79 |
| ▸ | F2 | P00734 | 2/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77424 | 0.89 | F10 (1.00) | F10F2ABCB11ST14 | |
| SCHEMBL77471 | 0.86 | F10 (0.94) | F10F2ABCB11ST14 | |
| SCHEMBL5479123 | 0.83 | F10 (0.71) | F10F2ABCB11ST14 | |
| SCHEMBL13722056 | 0.83 | F10 (0.80) | F10F2ABCB11ST14 | |
| SCHEMBL77993 | 0.82 | F10 (0.89) | F10F2ABCB11ST14 | |
| SCHEMBL21305662 | 0.81 | F10 (0.80) | F10F2ABCB11ST14 | |
| SCHEMBL23751580 | 0.81 | F10 (0.74) | F10F2ABCB11ST14 | |
| SCHEMBL8219680 | 0.81 | F10 (0.67) | F10F2ABCB11ST14 | |
| SCHEMBL4587228 | 0.81 | F10 (0.67) | F10F2ABCB11ST14 | |
| SCHEMBL1095489 | 0.80 | F10 (0.69) | F10F2ABCB11ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1626969-A1 | HETEROCYCLIC COMPOUNDS | Bayer HealthCare AG (DE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004101557-A1 | HETEROCYCLIC COMPOUNDS | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004101557-A1 | HETEROCYCLIC COMPOUNDS | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066615-A1 | Heterocyclic compounds | F2, SERPINC1, TFPI | F10 12/4885F2 1/4885ABCB11 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.